Forex volatility impacting reported margins
Mark-to-market forex losses of ₹41 crore in Q2 distorted EBITDA margin; continued volatility could mask underlying margin performance.
medium · management_commentaryAjanta Pharma Limited — Q2 FY26
Ajanta Pharma delivered a strong Q2 FY26 with consolidated revenue of ₹1,354 crore (+14% YoY) and PAT of ₹260 crore (+20% YoY).
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
IQVIA data anomaly in cardiac segment
Management acknowledged a gap between IQVIA-reported growth (6%) and internal sales growth (matching IPM's 12%) in cardiac, which could affect investor perception.
low · analyst_questionAfrica business unpredictability from aid agency procurement
Africa institutional (antimalarial) business remains dependent on unpredictable aid agency procurement, with revenue declining 17% in H1.
medium · management_commentaryWorking capital increase from factoring discontinuation
Trade receivables days increased to 101 from 94 due to switch from factoring to working capital loans, though management says it's P&L neutral.
low · data_observation